» Articles » PMID: 2686707

Comparison of the Computed Structures for the Phosphate-binding Loop of the P21 Protein Containing the Oncogenic Site Gly 12 with the X-ray Crystallographic Structures for This Region in the P21 Protein and EFtu. A Model for the Structure of the P21...

Overview
Date 1989 Apr 1
PMID 2686707
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The GTP-binding p21 protein encoded by the ras-oncogene can be activated to cause malignant transformation of cells by substitution of a single amino acid at critical positions along the polypeptide chain. Substitution of any non-cyclic L-amino acid for Gly 12 in the normal protein results in a transforming protein. This substitution occurs in a hydrophobic sequence (residues 6-15) which is known to be involved in binding the phosphate moities of GTP (and GDP). We find, using conformational energy calculations, that the 6-15 segment of the normal protein (with Gly 12) adopts structures that contain a bend at residues 11 and 12 with the Gly in the D* conformation, not allowed energetically for L-amino acids. Substitution of non-cyclic L-amino acids for Gly 12 results in shifting this bend to residues 12 and 13. We show that many computed structures for the Gly 12-containing phosphate binding loop, segment 9-15, are superimposable on the corresponding segment of the recently determined X-ray crystallographic structure for residues 1-171 of the p21 protein. All such structures contain bends at residues 11 and 12 and most of these contain Gly 12 in the C* or D* conformational state. Other computed conformations for the 9-15 segment were superimposable on the structure of the corresponding 18-23 segment of EFtu, the bacterial chain elongation factor having structural similarities to the p21 protein in the phosphate-binding regions. This segment contains a Val residue where a Gly occurs in the p21 protein. As previously predicted, all of these superimposable conformations contain a bend at positions 12 and 13, not 11 and 12. If these structures that are superimposable on EFtu are introduced into the p21 protein structure, bad contacts occur between the sidechain of the residue (here Val) at position 12 and another phosphate binding loop region around position 61. These bad contacts between the two segments can be removed by changing the conformation of the 61 region in the p21 protein to the corresponding position of the homologous region in EFtu. In this new conformation, a large site becomes available for the binding of phosphate residues. In addition, such phenomena as autophosphorylation of the p21 protein by GTP can be explained with this new model structure for the activated protein which cannot be explained by the structure for the non-activated protein.

Citing Articles

Lessons from computer simulations of Ras proteins in solution and in membrane.

Prakash P, Gorfe A Biochim Biophys Acta. 2013; 1830(11):5211-8.

PMID: 23906604 PMC: 3825463. DOI: 10.1016/j.bbagen.2013.07.024.


Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.

Bowne W, Michl J, Bluth M, Zenilman M, Pincus M Cancer Ther. 2007; 5B:331-344.

PMID: 18007958 PMC: 2078333.


Comparison of the average structures, from molecular dynamics, of complexes of GTPase activating protein (GAP) with oncogenic and wild-type ras-p21: identification of potential effector domains.

Chen J, Friedman F, Brandt-Rauf P, Pincus M, Chie L J Protein Chem. 2002; 21(5):349-59.

PMID: 12206509 DOI: 10.1023/a:1019994302273.


Identification, using molecular dynamics, of an effector domain of the ras-binding domain of the raf-p74 protein that is uniquely involved in oncogenic ras-p21 signaling.

Chen J, Rijhwani K, Friedman F, Hyde M, Pincus M J Protein Chem. 2001; 19(7):545-51.

PMID: 11233167 DOI: 10.1023/a:1007127700199.


Molecular dynamics on complexes of ras-p21 and its inhibitor protein, rap-1A, bound to the ras-binding domain of the raf-p74 protein: identification of effector domains in the raf protein.

Chen J, Monaco R, Manolatos S, Brandt-Rauf P, Friedman F, Pincus M J Protein Chem. 1997; 16(6):619-29.

PMID: 9263124 DOI: 10.1023/a:1026322924424.